Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03452293 · ClinicalTrials.gov registry record
SUPERa Stenting After SUBintimal Crossing of TASC C-D Femoro-popliteal Lesions in CLI Patients
A clinical trial of PAD, sponsored by EndoCore Lab s.r.l..
- Completed
- Registry status
- 92
- Enrollment target
- 15
- Study locations
NCT03452293 is a study of PAD that has completed, run by EndoCore Lab s.r.l.. The registered enrollment target is 92 participants, below the 138-participant average among 3 other PAD trials with a reported enrollment target (33% lower). The trial reports 15 study locations across 14 states.
The verdict
NCT03452293, a study of PAD, has completed, sponsored by EndoCore Lab s.r.l..
- COMPLETED
- Registry status
- 92 participants
- Enrollment target
- 15
- Study locations
Study Summary
The study will evaluate the safety and efficacy of subintimal Supera stenting in complex de novo or re-occlusive CTO (TASC C-D) lesions in patients with CLI. This study will be performed based on a rigorous sample size calculation, which will allow us to have the statistical power to validate our conclusions and therefore establish the generalizability of this strategy.
Conditions Studied
Interventions
- DEVICE Stent Peripheral System
Study Locations (15)
RM
- Policlinico Tor Vergata - Roma
- A.O. San Giovanni Addolorata - Roma
Michigan
- Metro Health Hospital - Wyoming
Santa Fe Province
- Instituto Medico CENICLAR, Unidad Sanatorio de la Mujer - Rosario
AQ
- Ospedale di Avezzano - Avezzano
CE
- Clinica San Michele - Maddaloni
CT
- A.O.U. Policlinico Vittorio Emanuele - Catania
LE
- A.O. Cardinale Panico - Tricase
Padova
- Casa di Cura Abano Terme - Abano Terme
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2018-03-07 |
| Est. Completion | 2022-03-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03452293
The ClinicalTrials.gov registry entry for NCT03452293 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 138-participant average among 3 other PAD trials with a reported enrollment target (33% lower). The listed sponsor is EndoCore Lab s.r.l., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PAD appearing as the primary indexed condition, and to 1 intervention - of which Stent Peripheral System is the first listed.
NCT03452293 reports 15 study locations spanning 14 distinct geographic areas - top geographies include RM, Michigan, Santa Fe Province.
Frequently Asked Questions
What is clinical trial NCT03452293 about?
NCT03452293 is a clinical study titled "SUPERa Stenting After SUBintimal Crossing of TASC C-D Femoro-popliteal Lesions in CLI Patients". The study will evaluate the safety and efficacy of subintimal Supera stenting in complex de novo or re-occlusive CTO (TASC C-D) lesions in patients with CLI. This study will be performed based on a rigorous sample size calculation, which will allow us to have the statistical power to validate our co...
What is the current status of trial NCT03452293?
This trial is currently completed. The enrollment target is 92 participants. The study started on 2018-03-07. Estimated completion is 2022-03-28.
What conditions does trial NCT03452293 study?
This clinical trial studies the following conditions: PAD.
What interventions are being tested in trial NCT03452293?
The interventions under investigation include: Stent Peripheral System (DEVICE).
Who is sponsoring clinical trial NCT03452293?
This trial is sponsored by EndoCore Lab s.r.l., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03452293 being conducted?
This trial has 15 study locations across Michigan, Santa Fe Province, AQ, CE, CT. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PAD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.